HomeProductsAnalytical StandardsDrug ImpuritiesCaptopril ImpurityTroxacitabine
Chemical structure of CAS 145918-75-8

Troxacitabine

In Stock•Starting at $132 for 2 mg•Purity ≥ 98%
CAS No.145918-75-8
MDL No.N/A
MFC8H11N3O4
MW213.19
InChI KeyRXRGZNYSEHTMHC-BQBZGAKWSA-N
CUSTOM SYNTHESISPRECLINICAL SUPPORT

Pricing & Availability

Pack SizePurityPriceAvailabilityAction
2 mg98%$132In Stock
5 mg98%$222In Stock
10 mg98%$376In Stock
Custom synthesis and bulk supply options are available upon request.

Product Information

Troxacitabine is a nucleobase-containing carbohydrate derivative.

CAS No.145918-75-8
Product NameTroxacitabine

Biological Targets

POLA1·POLD4·POLD3·POLD1·POLD2·

Associated Conditions

leukemia
* The information provided here is compiled from public sources and is for reference only.

Related Articles

Studies related to this compound and its mechanism of action

Troxacitabine, an L-stereoisomeric nucleoside analog, on a five-times-daily schedule: a phase I and pharmacokinetic study in patients with advanced solid malignancies.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology • Vol. 20, Issue 1 • 2002
PMID: 11773159DOI: 10.1200/JCO.2002.20.1.96

Novel agents for the therapy of acute leukemia.

Current opinion in oncology • Vol. 14, Issue 1 • 2002
PMID: 11790973DOI: 10.1097/00001622-200201000-00002

Phase II study of troxacitabine, a novel dioxolane nucleoside analog, in patients with refractory leukemia.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology • Vol. 20, Issue 3 • 2002
PMID: 11821445DOI: 10.1200/JCO.2002.20.3.656

Troxacitabine, a novel dioxolane nucleoside analog, has activity in patients with advanced leukemia.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology • Vol. 19, Issue 3 • 2001
PMID: 11157029DOI: 10.1200/JCO.2001.19.3.762

Documentation

Similar Products